Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in

Full article: Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults

Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong

Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study - ScienceDirect

CoronaVac, BNT162b2 and heterologous COVID-19 vaccine outcomes in patients with ventricular assist device - Mehmet Karahan, Umit Kervan, Sinan Sabit Kocabeyoglu, Dogan Emre Sert, Yasemin Tezer Tekce, Omer Abdullah Yavuz, Seref Alp

Longer-term effectiveness of a heterologous coronavirus disease 2019 (COVID-19) vaccine booster in healthcare workers in Brazil, Antimicrobial Stewardship & Healthcare Epidemiology

Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case–control study

Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial - The Lancet Regional Health – Western Pacific

Effectiveness of BNT162b2 and CoronaVac vaccines against omicron in children aged 5 to 11 years

Antibody Responses and Reactogenicity of a Heterologous, Full-Dose Messenger RNA-1273 Booster in Heavily SARS-CoV-2–Exposed CoronaVac- Vaccinated Health-Care Workers in Indonesia: A Real-World Observational Study in: The American Journal of Tropical

Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022

Farmacovigilancia de vacunas para COVID-19 - Sinovac

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Effectiveness of BNT162b2 and CoronaVac vaccines against omicron in children aged 5 to 11 years

Study compares efficacy of BNT162b2 and CoronaVac as the booster dose for COVID-19 vaccination

Vaccines, Free Full-Text